Pompano Beach, Fla., April 27, 2015 (GLOBE NEWSWIRE) -- DS Healthcare Group, Inc. (DSKX), a leading developer of personal care products, today announced that it will begin shipping its Integra® hair growth support tablets to Mexico and other international markets. This announcement comes on the heels of the Continuum launch on April 24th.
Integra® contains a unique composition of ingredients and it is the first oral tablet to contain Astressin-B and Oenothein-B. Astressin-B is a complex peptide that has shown in landmark research that it can reduce the effects of Corticotropin-releasing hormone (CRH) involved in the stress response. CRH is associated with many other diseases and is also believed to have a direct impact on hair loss, particularly in people who are currently predisposed to hair loss and thinning hair.
"Hair loss supplement tablets have recently gained significant popularity, particularly in the European and South American markets. Our competitors produce tablets that are primarily vitamin and mineral based, and are generally known to have limited efficacy other than in people who are deficient in certain nutrients. Another alternative is finasteride therapy which carries the potential risk of adverse side effects. We view our new Integra® tablet as truly revolutionary, with an entirely new mechanism of action. We are extremely excited about its efficacy and the impact it will have to further improve results. Physicians will now be provided with this meaningful tool to help combat hair loss issues. This will also potentially be a big revenue driver for our Company and shareholders in various international markets" stated DS Healthcare President and CEO Daniel Khesin.
Fernando Tamez, M.D., CEO of Divine Skin Laboratories S.A., a wholly owned subsidiary in Mexico of DS Healthcare Group added, "our distribution is growing very rapidly and we are anticipating strong demand for a new tablet such as Integra which is expected to contribute to our nearly 30% year-over-year revenue increase. After 2 years of research and development our customers are thrilled that it's finally here and our network of dermatologists are eager and ready to begin recommending it in their practices. There has never been anything like this in our market and the acceptance of Integra will fit perfectly in our rapidly expanding and growing model in Mexico."
About DS Healthcare Group
DS Healthcare Group Inc. leads in the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Health Group's flagship brand, visit www.dslaboratories.com
Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies, and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov.
CONTACT: Abner Silva DS Healthcare Group 407.342.4112 Abner@DSHealthgroup.com
Source:DS Healthcare Group, Inc.